Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.54 |
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | HTR2B | P41595 | 1/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.46 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.46 |
| ▸ | CTSA | P10619 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.40 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21056883 | 1.00 | TSHR (0.54) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL16348373 | 0.83 | PPARG (0.55) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL16348372 | 0.82 | PPARG (0.56) | PTGDR2CTSAPPARGPPARATRPM4 | |
| SCHEMBL21056936 | 0.77 | TSHR (0.56) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL21056934 | 0.77 | TSHR (0.56) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL21056890 | 0.77 | TSHR (0.56) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL21056985 | 0.77 | TSHR (0.56) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL21056989 | 0.77 | TSHR (0.56) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL21057040 | 0.77 | TSHR (0.56) | TSHRHTR2AHTR2CHTR2BPTGDR2 | |
| SCHEMBL21056892 | 0.77 | TSHR (0.56) | TSHRHTR2AHTR2CHTR2BPTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | claimed |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-10-14 | — | — | US | claimed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | claimed |
| CN-111712489-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-11-07 | — | — | CN | claimed |
| EP-3724173-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2021-09-22 | — | — | EP | claimed |
| CN-111712489-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-09-25 | — | — | CN | claimed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | claimed |
| EP-4731200-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD Pharma A/S (DK) | 2026-04-29 | — | — | EP | disclosed |
| US-20260007639-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA A/S (DK) | 2026-01-08 | — | — | US | disclosed |
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | NMD PHARMA A/S (DK) | 2025-10-14 | — | — | US | disclosed |
| WO-2024261020-A1 | CLC-1 INHIBITORS FOR USE IN THE TREATMENT OF MULTIPLE SCLEROSIS AND NEUROMUSCULAR DISEASES | NMD PHARMA A/S (DK) | 2024-12-26 | — | — | WO | disclosed |
| CN-111712489-B | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2023-11-07 | — | — | CN | disclosed |
| EP-3724173-B1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | NMD PHARMA AS (DK) | 2021-09-22 | — | — | EP | disclosed |
| CN-111712489-A | Compounds for the treatment of neuromuscular disorders | NMD制药股份公司 | 2020-09-25 | — | — | CN | disclosed |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | NMD PHARMA A/S (DK) | 2019-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12440477-B2 | Compounds for the treatment of neuromuscular disorders | RYR1, CACNB1, RYR2 | TSHR 3626/4885HTR2A 3861/4885HTR2C 4504/4885 |
| US-20190183863-A1 | Compounds For The Treatment Of Neuromuscular Disorders | RYR1, CACNB1, RYR2 | TSHR 3626/4885HTR2A 3861/4885HTR2C 4504/4885 |
| US-20260007639-A1 | COMPOUNDS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS | RYR1, CLIC1, RYR2 | TSHR 934/4885HTR2A 3337/4885HTR2C 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.